Prediction of LVAR and MACE in AMI Though Plasma Multiomics Analysis

NCT06885619 | Active Not Recruiting DMC

• 1 other identifier: KS2025013
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.

Conditions

Acute Myocardial Infarction (AMI); Left Ventricular Remodeling; Major Adverse Cardiovascular Event; Plasma Multi-Omics

Outcome Measures

Primary Outcomes (1)

• major adverse cardiovascular events

  Identify T0 plasma multi-omics biomarkers that predict cardiac death, myocardial infarction, heart failure, and stroke.

  2025-1-1 to 2027-12-31

Secondary Outcomes (1)

• adverse cardiac remodeling

  2025-1-1 to 2027-12-31

Study Arms (1)

Patients with AMI

Patients diagnosed with AMI (ST-segment elevation myocardial infarction \[STEMI\] and non-ST-segment elevation myocardial infarction \[NSTEMI\])

Other: Diagnostic Test: echocardiography and blood collection

Interventions

Diagnostic Test: echocardiography and blood collection OTHER

Blood samples were collected from all patients at the time of myocardial infarction (MI) diagnosis. For those with acute ST-elevation myocardial infarction, blood samples were taken on the day of diagnosis(T0), as well as two days (T1), one week (T2) and one month (T3) after percutaneous coronary intervention (PCI). Echocardiography was performed at the time of STEMI diagnosis, and then again at one week, one month, and six months post-onset.

Patients with AMI

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population includes individuals diagnosed with acute myocardial infarction (MI), selected by the site personnel according to predefined inclusion criteria. The cohort comprises 1,000 patients, whose baseline clinical characteristics and plasma biomarkers will be assessed.

You may qualify if:

• Age ≥ 18 years.
• Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).
• Willingness to provide informed consent.

You may not qualify if:

• Prior surgery or trauma.
• Renal failure with glomerular filtration \<30 ml/min.

Sponsors & Collaborators

• Beijing Anzhen Hospital: lead

Study Sites (1)

Beijing Anzhen Hospital, Capital Medical University.

Beijing, Beijing Municipality, 100029, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Whole blood samples were centrifuged to separate plasma, which was then aliquoted and stored at -80°C for long-term preservation

MeSH Terms

Conditions

Ventricular Remodeling

Condition Hierarchy (Ancestors)

Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Xu Wang, Dr.

  Beijing Anzhen hospital, Capital Mediacl University.

  PRINCIPAL INVESTIGATOR

• Tanxi Cai, Dr.

  Institute of Biophysics, Chinese Academy of Sciences

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 14, 2025
• First Posted: March 20, 2025
• Study Start: January 1, 2025
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: July 31, 2025

Record last verified: 2025-02

Locations

CN (1)